BSE Code: 524764
Last Close: Rs.19.25
NutraPlus India Ltd. (NPIL) is a limited company. It was incorporated as a private limited company in February 1990 and commenced the manufacture of APIs and Intermediates in 1995 for the domestic and overseas markets. Its product portfolio includes N Bromo Succinimide, a brominating compound; N Methyl Nitro Guanidine, an intermediate for insecticides; Chlorhexidine Gluconate, an anti infectant; 7-hloroQuinaldine, an intermediate of the Montelukast drug; and M Bromo Anisole, an intermediate of API Tramadol HCL.It has an equity base of Rs.5.20 crore that is supported by reserves of around Rs.4.64 crore. The promoters hold 48.31%, non-promoter corporate bodies hold 1.93%, foreign investors hold 4.85% while the investing public holds 44.84% stake in the company.The Q3FY12 EPS is Rs.2.10 while the nine monthly EPS is Rs.6.06. At the current level, the stock is available at a P/E multiple of just 2.3.
Just look at its past performance. Every year, the stock has shown fantastic growth in sales and volume, which indicates that the company will do well in future. At the current level, the stock is available at a throwaway price as per the P/E ratio. We are, therefore, recommending to buy this stock for medium-to-long-term investment as the company may report an EPS of Rs.8+ for FY12 and may declare dividend this year. Investors can buy this stock with stop loss of Rs.17. On the upper side, the stock will zoom to Rs.26-30 levels in the medium-to-long-term.
Last Close: Rs.19.25
NutraPlus India Ltd. (NPIL) is a limited company. It was incorporated as a private limited company in February 1990 and commenced the manufacture of APIs and Intermediates in 1995 for the domestic and overseas markets. Its product portfolio includes N Bromo Succinimide, a brominating compound; N Methyl Nitro Guanidine, an intermediate for insecticides; Chlorhexidine Gluconate, an anti infectant; 7-hloroQuinaldine, an intermediate of the Montelukast drug; and M Bromo Anisole, an intermediate of API Tramadol HCL.It has an equity base of Rs.5.20 crore that is supported by reserves of around Rs.4.64 crore. The promoters hold 48.31%, non-promoter corporate bodies hold 1.93%, foreign investors hold 4.85% while the investing public holds 44.84% stake in the company.The Q3FY12 EPS is Rs.2.10 while the nine monthly EPS is Rs.6.06. At the current level, the stock is available at a P/E multiple of just 2.3.
Just look at its past performance. Every year, the stock has shown fantastic growth in sales and volume, which indicates that the company will do well in future. At the current level, the stock is available at a throwaway price as per the P/E ratio. We are, therefore, recommending to buy this stock for medium-to-long-term investment as the company may report an EPS of Rs.8+ for FY12 and may declare dividend this year. Investors can buy this stock with stop loss of Rs.17. On the upper side, the stock will zoom to Rs.26-30 levels in the medium-to-long-term.
No comments:
Post a Comment